- Home
- FTDR vs ADMA Comparison
FTDR vs ADMA Comparison
Compare FTDR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- ADMA
- Stock Information
- Founded
- FTDR 1971
- ADMA 2004
- Country
- FTDR United States
- ADMA United States
- Employees
- FTDR N/A
- ADMA N/A
- Industry
- FTDR Diversified Commercial Services
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTDR Finance
- ADMA Health Care
- Exchange
- FTDR Nasdaq
- ADMA Nasdaq
- Market Cap
- FTDR 4.4B
- ADMA 5.1B
- IPO Year
- FTDR 2018
- ADMA N/A
- Fundamental
- Price
- FTDR $59.76
- ADMA $17.80
- Analyst Decision
- FTDR Hold
- ADMA Strong Buy
- Analyst Count
- FTDR 4
- ADMA 3
- Target Price
- FTDR $59.75
- ADMA $27.67
- AVG Volume (30 Days)
- FTDR 740.7K
- ADMA 3.3M
- Earning Date
- FTDR 08-05-2025
- ADMA 08-06-2025
- Dividend Yield
- FTDR N/A
- ADMA N/A
- EPS Growth
- FTDR 29.61
- ADMA 469.09
- EPS
- FTDR 3.36
- ADMA 0.85
- Revenue
- FTDR $1,966,000,000.00
- ADMA $474,174,000.00
- Revenue This Year
- FTDR $12.86
- ADMA $21.11
- Revenue Next Year
- FTDR $6.54
- ADMA $25.97
- P/E Ratio
- FTDR $17.78
- ADMA $20.93
- Revenue Growth
- FTDR 8.62
- ADMA 43.58
- 52 Week Low
- FTDR $35.61
- ADMA $13.50
- 52 Week High
- FTDR $64.91
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- FTDR 56.90
- ADMA 51.09
- Support Level
- FTDR $58.24
- ADMA $16.93
- Resistance Level
- FTDR $60.62
- ADMA $17.90
- Average True Range (ATR)
- FTDR 2.34
- ADMA 0.86
- MACD
- FTDR 0.19
- ADMA 0.04
- Stochastic Oscillator
- FTDR 63.59
- ADMA 59.11
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.